Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b ...
Feb 18 () - Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed better results in patients with the skin disease and obesity in a late-stage study ...
Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection. Botulinum toxin A (BoNT-A) injection emerged as an effective therapy for patients ...
The webinar will be broadcast via Zoom. Interested participants can register using the following LINK. The discussion will provide an in-depth exploration of the plaque psoriasis landscape, current ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Picankibart is a recombinant anti-interleukin 23p19 ...
Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...
NEW YORK (Reuters Health) - Injections of a protein called interleukin-4 (IL-4) seem equal to the best therapy now available for relieving symptoms of the chronic skin condition psoriasis, the results ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Should you see ...
Innovent’s psoriasis contender to IL-23 drugs like Tremfya and Skyrizi cleared skin and improved the severity of disease in a phase 3 test, setting up the company to seek approval from Chinese ...
At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results